Ulrike Bauder‐Wüst

3.4k total citations · 3 hit papers
36 papers, 2.8k citations indexed

About

Ulrike Bauder‐Wüst is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Ulrike Bauder‐Wüst has authored 36 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Radiology, Nuclear Medicine and Imaging, 21 papers in Pulmonary and Respiratory Medicine and 17 papers in Oncology. Recurrent topics in Ulrike Bauder‐Wüst's work include Radiopharmaceutical Chemistry and Applications (23 papers), Prostate Cancer Treatment and Research (21 papers) and Peptidase Inhibition and Analysis (16 papers). Ulrike Bauder‐Wüst is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (23 papers), Prostate Cancer Treatment and Research (21 papers) and Peptidase Inhibition and Analysis (16 papers). Ulrike Bauder‐Wüst collaborates with scholars based in Germany, United States and Czechia. Ulrike Bauder‐Wüst's co-authors include Martin Schäfer, Uwe Haberkorn, Matthias Eder, Walter Mier, Klaus Kopka, Michael Eisenhut, Martina Benešová, Carmen Wängler, Ali Afshar‐Oromieh and Clemens Kratochwil and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Bioconjugate Chemistry.

In The Last Decade

Ulrike Bauder‐Wüst

36 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

⁶⁸Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging

2012 688 citations Matthias Eder, Martin Schäfer et al. profile →
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer

2015 464 citations Martina Benešová, Martin Schäfer et al. Journal of Nuclear Medicine profile →
Novel Preclinical and Radiopharmaceutical Aspects of [68Ga]Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer

2014 317 citations Matthias Eder, Oliver Neels et al. Pharmaceuticals profile →

Peers

Countries citing papers authored by Ulrike Bauder‐Wüst

Since Specialization

Citations

This map shows the geographic impact of Ulrike Bauder‐Wüst's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ulrike Bauder‐Wüst with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ulrike Bauder‐Wüst more than expected).

Fields of papers citing papers by Ulrike Bauder‐Wüst

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ulrike Bauder‐Wüst. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ulrike Bauder‐Wüst. The network helps show where Ulrike Bauder‐Wüst may publish in the future.

Co-authorship network of co-authors of Ulrike Bauder‐Wüst

This figure shows the co-authorship network connecting the top 25 collaborators of Ulrike Bauder‐Wüst. A scholar is included among the top collaborators of Ulrike Bauder‐Wüst based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ulrike Bauder‐Wüst. Ulrike Bauder‐Wüst is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Structure–Activity Relationships and Biological Insights into PSMA-617 and Its Derivatives with Modified Lipophilic Linker Regions 2025 ·ACS Omega ·Martin Schäfer, Ulrike Bauder‐Wüst, Mareike Roscher, L. Motlova, Zsófia Kutil, Yvonne Remde, Karel D. Klika, Jürgen Graf, Cyril Bařinka, (unknown)	4
2	Synthesis of tritium-labeled Lu-PSMA-617: Alternative tool for biological evaluation of radiometal-based pharmaceuticals 2023 ·Applied Radiation and Isotopes ·Ulrike Bauder‐Wüst, Martin Schäfer, (unknown), Yvonne Remde, Mareike Roscher, (unknown), Thorsten Poethko, Csaba Tömböly, (unknown)	1
3	A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer 2022 ·Pharmaceuticals ·(unknown), Jessica Matthias, Martin Schäfer, Jana Schmidt, (unknown), Ulrike Bauder‐Wüst, (unknown), Mareike Roscher, Uwe Haberkorn, Matthias Eder, Klaus Kopka	6
4	Refined Chelator Spacer Moieties Ameliorate the Pharmacokinetics of PSMA-617 2022 ·Frontiers in Chemistry ·(unknown), Martin Schäfer, Ulrike Bauder‐Wüst, Barbro Beijer, Matthias Eder, Karin Leotta, Christian Kleist, Jan‐Philip Meyer, Thomas R. Dilling, Jason S. Lewis, Clemens Kratochwil, Klaus Kopka, Uwe Haberkorn, Walter Mier	2
5	Cytoplasmic Localization of Prostate-Specific Membrane Antigen Inhibitors May Confer Advantages for Targeted Cancer Therapies 2021 ·Cancer Research ·Jessica Matthias, Johann Engelhardt, Martin Schäfer, Ulrike Bauder‐Wüst, Philipp T. Meyer, Uwe Haberkorn, Matthias Eder, Klaus Kopka, Stefan W. Hell, (unknown)	21
6	Rational Linker Design to Accelerate Excretion and Reduce Background Uptake of Peptidomimetic PSMA-Targeting Hybrid Molecules 2021 ·Journal of Nuclear Medicine ·(unknown), Martin Schäfer, Jana Schmidt, Ulrike Bauder‐Wüst, Mareike Roscher, Karin Leotta, Uwe Haberkorn, Klaus Kopka, Matthias Eder	16
7	Development of PSMA-1007-Related Series of ¹⁸F-Labeled Glu-Ureido-Type PSMA Inhibitors 2020 ·Journal of Medicinal Chemistry ·Jens Cardinale, Mareike Roscher, Martin Schäfer, (unknown), (unknown), Ulrike Bauder‐Wüst, Yvonne Remde, Matthias Eder, Zora Nováková, L. Motlova, Cyril Bařinka, Frederik L. Giesel, Klaus Kopka	24
8	Bicyclic Peptides as a New Modality for Imaging and Targeting of Proteins Overexpressed by Tumors 2019 ·Cancer Research ·Matthias Eder, Silvia Pavan, Ulrike Bauder‐Wüst, Katerine Van Rietschoten, (unknown), (unknown), (unknown), Catherine Stace, Edward H. Walker, Liuhong Chen, Gavin Bennett, Gemma Mudd, (unknown), Karin Leotta, Uwe Haberkorn, Klaus Kopka, Daniel P. Teufel	49
9	Development of Novel PSMA Ligands for Imaging and Therapy with Copper Isotopes 2019 ·Journal of Nuclear Medicine ·(unknown), Barbro Beijer, Ulrike Bauder‐Wüst, Martin Schäfer, Karin Leotta, Matthias Eder, Martina Benešová, Christian Kleist, Frederik L. Giesel, Clemens Kratochwil, Klaus Kopka, Uwe Haberkorn, Walter Mier	31
10	PSMA-11–Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer 2017 ·Journal of Nuclear Medicine ·(unknown), Martin Schäfer, Ulrike Bauder‐Wüst, Mareike Roscher, Jana Schmidt, (unknown), Tobias Simpfendörfer, Doğu Teber, Lena Maier‐Hein, Boris Hadaschik, Uwe Haberkorn, Matthias Eder, Klaus Kopka	101
11	Preclinical Evaluation of ¹⁸F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging 2016 ·Journal of Nuclear Medicine ·Jens Cardinale, Martin Schäfer, Martina Benešová, Ulrike Bauder‐Wüst, Karin Leotta, Matthias Eder, Oliver Neels, Uwe Haberkorn, Frederik L. Giesel, Klaus Kopka	195
12	Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer breakdown → 2015 ·Journal of Nuclear Medicine ·Martina Benešová, Martin Schäfer, Ulrike Bauder‐Wüst, Ali Afshar‐Oromieh, Clemens Kratochwil, Walter Mier, Uwe Haberkorn, Klaus Kopka, Matthias Eder	464
13	Synthesis and in vitro evaluation of 68Ga-DOTA-4-FBn-TN14003, a novel tracer for the imaging of CXCR4 expression 2012 ·Bioorganic & Medicinal Chemistry ·Ute Hennrich, Lisa Seyler, Martin Schäfer, Ulrike Bauder‐Wüst, Michael Eisenhut, Wolfhard Semmler, Tobias Bäuerle	24
14	A dimerized urea-based inhibitor of the prostate-specific membrane antigen for 68Ga-PET imaging of prostate cancer 2012 ·EJNMMI Research ·Martin Schäfer, Ulrike Bauder‐Wüst, Karin Leotta, Frederic Zoller, Walter Mier, Uwe Haberkorn, Michael Eisenhut, Matthias Eder	145
15	Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275 2010 ·European Journal of Nuclear Medicine and Molecular Imaging ·Annette Altmann, Michael Eisenhut, Ulrike Bauder‐Wüst, Annette Markert, Vasileios Askoxylakis, Holger Hess‐Stumpp, Uwe Haberkorn	14
16	Multivalent cyclic RGD ligands: influence of linker lengths on receptor binding 2010 ·Nuclear Medicine and Biology ·(unknown), Martin Schäfer, Ulrike Bauder‐Wüst, Matthias Eder, (unknown), Uwe Haberkorn, Walter Mier, Michael Eisenhut	36
17	Role of acidic cell organelles in the higher nonmelanoma retention of melanoma markers based on N-(2-dialkylaminoethyl)benzamides and the cytotoxicity of alkylating benzamides 2007 ·Melanoma Research ·Markus Wolf, Ulrike Bauder‐Wüst, (unknown), Claudia S. Bauer, Michael Eisenhut	2
18	Fluorophor-labeled spermidine derivatives as fluorescent markers in optical tumor imaging 2006 ·Bioorganic & Medicinal Chemistry Letters ·Markus Wolf, Ulrike Bauder‐Wüst, Rüdiger Pipkorn, (unknown), Michael Eisenhut	9
19	Efficacy and tolerability of an aminopterin–albumin conjugate in tumor-bearing rats 2002 ·Anti-Cancer Drugs ·Paul Kremer, G. Hartung, Ulrike Bauder‐Wüst, (unknown), Andreas Wunder, Stefan Heckl, U Zillmann, Hannsjörg Sinn	11
20	Cytosine deaminase and thymidine kinase gene therapy in a Dunning rat prostate tumour model: absence of bystander effects and characterisation of 5-fluorocytosine metabolism with 19F-NMR spectroscopy 2002 ·Gene Therapy ·(unknown), William E. Hull, G. Becker, Ulrike Bauder‐Wüst, (unknown), Jürgen Debus	19

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact